⌘K
Loading ticker…
As of 2026-08-24, Atea Pharmaceuticals, Inc. Common Stock (AVIR) has a 3-month relative strength percentile of 85 within the TickerStance CS+ADRC universe (~5,000 tickers). Its Power rating (absolute 1–99) is 62. The current market Stance is 47.8 (Neutral). Sector: Healthcare, ranked 3 of 11. Average daily range 6.5%, relative volume 0.26×. TickerStance reports observed regime conditions across the full CS+ADRC universe; band assignment reflects current breadth, momentum, and macro inputs computed at the daily close. Percentile ranks run from 1 (weakest) to 99 (strongest) relative to all universe members on the same date.
AVIR is in a stage 3 topping pattern, week 6. Currently in a 116-day base; basing ADR 5.0% (broad 5.0%). VCP detected: inconclusive. RS line below base-start high. Distance from 50d / 200d: 14.5% / 22.3%.
Relative strength across horizons plus the leadership score.
Accumulation rating, relative volume, U/D ratio, breakout-day proof.
Diluted EPS, last 8 quarters. Loss makers are judged by progress toward breakeven.
AVIR is held by 19 ETFs as of May 2026. Top owner: VTWO at 0.01% weight, $2M notional. Top 3 carry $4M.
Held by 37 ETFs · $42M across latest filings · largest weight 0.24% (SBIO).
Top 10 by value, from SEC N-PORT-P filings dated May 2026.
| ETF | Weight | Value | Δ |
|---|---|---|---|
| VTWO | 0.01% | $2M | — |
| SCHASchwab U.S. Small-Cap ETF | 0.01% | $2M | — |
| VHTVanguard Health Care ETF | 0.00% | $718K | — |
| AVSC | 0.03% | $709K | — |
| SBIO | 0.24% | $384K | — |
Strong relative strength, but attention is quiet relative to this name’s own recent norm. Academic work links low public attention to better forward returns on average — context to weigh, not a forecast.
Measures how unusual this name’s public attention is against its own 90-day history — a surprise reading, not a ranking of how watched it is versus other stocks. Intel, not a signal.
Daily range, ATR, beta, and the math for a 1-ADR stop.
YoY sales growth, last 8 quarters. Sales must back the earnings story.
Operating margin unavailable
YoY common shares outstanding. Down = buyback tailwind. Up > 2% = dilution flag.
Reported figures from SEC filings. No analyst estimates or forward guidance.
| 0.00% |
| $325K |
| — |
| VTWV | 0.02% | $252K | — |
| SCHBSchwab U.S. Broad Market ETF | 0.00% | $221K | — |
| AVUSAvantis U.S. Equity ETF | 0.00% | $52K | — |
| OMFS | 0.02% | $46K | new |
Showing 10 of 19 ETF owners.
As filed in N-PORT — quarterly holdings with up to ~60-day publication lag. Not live positioning.
Related searches
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | AVIR Jan avg: 10.69% median: 7.51% win: 50% σ: 20.89% n: 4 2022-04-12 → 2026-07-31 | AVIR Feb avg: -2.63% median: 1.31% win: 50% σ: 14.70% n: 4 2022-04-12 → 2026-07-31 | AVIR Mar avg: 0.50% median: -3.34% win: 25% σ: 9.87% n: 4 2022-04-12 → 2026-07-31 | AVIR Apr avg: -4.08% median: -2.39% win: 20% σ: 5.35% n: 5 2022-04-12 → 2026-07-31 | AVIR May avg: 8.18% median: 0.68% win: 60% σ: 19.73% n: 5 2022-04-12 → 2026-07-31 | AVIR Jun avg: -1.04% median: -6.27% win: 20% σ: 13.02% n: 5 2022-04-12 → 2026-07-31 | AVIR Jul avg: 4.96% median: 1.11% win: 80% σ: 10.31% n: 5 2022-04-12 → 2026-07-31 | AVIR Aug avg: -4.37% median: -4.87% win: 25% σ: 4.49% n: 4 2022-04-12 → 2026-07-31 (current) | AVIR Sep avg: -15.38% median: -13.34% win: 0% σ: 5.97% n: 4 2022-04-12 → 2026-07-31 | AVIR Oct avg: 5.64% median: 6.89% win: 75% σ: 6.54% n: 4 2022-04-12 → 2026-07-31 | AVIR Nov avg: -7.22% median: -6.31% win: 25% σ: 11.32% n: 4 2022-04-12 → 2026-07-31 | AVIR Dec avg: 4.42% median: 2.28% win: 75% σ: 7.45% n: 4 2022-04-12 → 2026-07-31 |